Table 5.

Top 10 most-cited articles on immunotherapy for endometrial cancer.

Title	First author	Source title	Publication yr	Total citations	Average citations per yr
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial	Makker, Vicky	LANCET ONCOLOGY	2019	287	57.4
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study	Ott, Patrick A.	JOURNAL OF CLINICAL ONCOLOGY	2017	278	39.71
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer	Mehnert, Janice M.	JOURNAL OF CLINICAL INVESTIGATION	2016	266	33.25
Current recommendations and recent progress in endometrial cancer	Brooks, Rebecca A.	CA-A CANCER JOURNAL FOR CLINICIANS	2019	257	51.4
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer	Makker, Vicky	JOURNAL OF CLINICAL ONCOLOGY	2020	224	56
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors	Taylor, Matthew H.	JOURNAL OF CLINICAL ONCOLOGY	2020	192	48
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer	Makker, V	NEW ENGLAND JOURNAL OF MEDICINE	2022	160	80
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial	Oaknin, Ana	JAMA ONCOLOGY	2020	135	33.75
Regression of Chemotherapy-Resistant Polymerase epsilon (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab	Santin, Alessandro D.	CLINICAL CANCER RESEARCH	2016	113	14.13
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives	Ventriglia, Jole	CANCER TREATMENT REVIEWS	2017	102	14.57